1. Therapeutic dormancy to delay postsurgical glioma recurrence: the past, present and promise of focal hypothermia

   • Didier Wion

   Topic Review 17 May 2017 Pages: 447 - 454

   

2. The role of bevacizumab in the treatment of glioblastoma

   • Roberto Jose Diaz
   • Sheikh Ali
   • Ricardo J. Komotar

   Topic Review 19 May 2017 Pages: 455 - 467

   

3. Next-Generation Sequencing-based genomic profiling of brain metastases of primary ovarian cancer identifies high number of BRCA-mutations

   • S. Balendran
   • S. Liebmann-Reindl
   • M. Preusser

   Laboratory Investigation Open access 11 May 2017 Pages: 469 - 476

4. MiR-181b modulates chemosensitivity of glioblastoma multiforme cells to temozolomide by targeting the epidermal growth factor receptor

   • Yunxiang Chen
   • Rui Li
   • Xiefeng Wang

   Laboratory Investigation 13 May 2017 Pages: 477 - 485

   

5. Study of β-catenin and BRAF alterations in adamantinomatous and papillary craniopharyngiomas: mutation analysis with immunohistochemical correlation in 54 cases

   • Prit Benny Malgulwar
   • Aruna Nambirajan
   • Mehar Chand Sharma

   Laboratory Investigation 12 May 2017 Pages: 487 - 495

   

6. Epithelial growth factor receptor expression influences 5-ALA induced glioblastoma fluorescence

   • Andrea O. Fontana
   • Deborah Piffaretti
   • Michael Reinert

   Laboratory Investigation Open access 12 May 2017 Pages: 497 - 507

   

7. Epigenetically controlled Six3 expression regulates glioblastoma cell proliferation and invasion alongside modulating the activation levels of WNT pathway members

   • Baoxin Zhang
   • Chenfu Shen
   • Zuping Zhang

   Laboratory Investigation 22 June 2017 Pages: 509 - 518

   

8. Evaluation of mitochondrial respiratory function in highly glycolytic glioma cells reveals low ADP phosphorylation in relation to oxidative capacity

   • Erika Rodrigues-Silva
   • Edilene S. Siqueira-Santos
   • Roger F. Castilho

   Laboratory Investigation 24 May 2017 Pages: 519 - 529

   

9. Radiotherapy for cranial and brain metastases from prostate cancer: a systematic review

   • Timothy L. Sita
   • Katarina G. Petras
   • Tim J. Kruser

   Clinical Study 25 May 2017 Pages: 531 - 538

   

10. Analysis of surgical and MRI factors associated with cerebellar mutism

    • Anjali Sergeant
    • Michelle Masayo Kameda-Smith
    • Nina Stein

    Clinical Study 19 May 2017 Pages: 539 - 552

    

11. MicroRNA-211 expression is down-regulated and associated with poor prognosis in human glioma

    • Jun Zhang
    • Jianguang Lv
    • Yuqian Li

    Clinical Study 27 May 2017 Pages: 553 - 559

    

12. Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series

    • Marc C. Chamberlain
    • Bryan T. Kim

    Clinical Study 12 May 2017 Pages: 561 - 569

    

13. Ischemic stroke and intracranial hemorrhage in patients with recurrent glioblastoma multiforme, treated with bevacizumab

    • Timo A. Auer
    • Mirjam Renovanz
    • Yasemin Tanyildizi

    Clinical Study 29 May 2017 Pages: 571 - 579

    

14. Embryonal tumors in Canadian children less than 36 months of age: results from the Canadian Pediatric Brain Tumor Consortium (CPBTC)

    • E. Story
    • D. L. Johnston
    • D. L. Keene

    Clinical Study 16 May 2017 Pages: 581 - 587

    

15. A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas

    • Priya Kumthekar
    • Sean Grimm
    • Jeffrey Raizer

    Clinical Study 16 May 2017 Pages: 589 - 594

    

16. Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma

    • Penny Fang
    • Wen Jiang
    • Jing Li

    Clinical Study 12 May 2017 Pages: 595 - 602

    

17. Seizure response to perampanel in drug-resistant epilepsy with gliomas: early observations

    • Charles Vecht
    • Alberto Duran-Peña
    • Gilles Huberfeld

    Clinical Study 10 May 2017 Pages: 603 - 607

18. Clinical presentation and prognostic indicators in 100 adults and children with neurofibromatosis 1 associated non-optic pathway brain gliomas

    • Susan Byrne
    • Steve Connor
    • Rosalie E. Ferner

    Clinical Study Open access 07 June 2017 Pages: 609 - 614

    

19. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma

    • Byung Sup Kim
    • Doo-Sik Kong
    • Jung-Il Lee

    Clinical Study 23 May 2017 Pages: 615 - 622

    

20. Health-related quality of life outcomes from CABARET: a randomized phase 2 trial of carboplatin and bevacizumab in recurrent glioblastoma

    • Kathryn M. Field
    • Madeleine T. King
    • Anna K. Nowak

    Clinical Study 22 May 2017 Pages: 623 - 631

    

21. Diffuse midline skull base meningiomas: identification of a rare and aggressive subgroup of meningiomas

    • Matthieu Peyre
    • Loïc Feuvret
    • Michel Kalamarides

    Clinical Study 23 May 2017 Pages: 633 - 639

    

22. The Simpson grading in meningioma surgery: does the tumor location influence the prognostic value?

    • Kira Marie Voß
    • Dorothee Cäcilia Spille
    • Benjamin Brokinkel

    Clinical Study 19 May 2017 Pages: 641 - 651

    

23. Factors associated with supportive care needs in glioma patients in the neuro-oncological outpatient setting

    • Mirjam Renovanz
    • Marlene Hechtner
    • Anne-Katrin Hickmann

    Clinical Study 19 May 2017 Pages: 653 - 662

    

24. Rapid resolution of leptomeningeal disease with targeted therapy in a metastatic melanoma patient

    • Isabella C. Glitza
    • Sherise D. Ferguson
    • Nandita Guha-Thakurta

    Letter to the Editor 20 May 2017 Pages: 663 - 665

    

25. MGMT promoter methylation status: time for a frank discussion

    • Niamh Coleman
    • Leslie Bridges
    • Frank Saran

    Letter to the Editor 30 May 2017 Pages: 667 - 668